Connect with Your Dermatology Provider from the Comfort of Your Home.
Due to the outbreak of COVID-19, healthcare professionals are now connecting virtually for recommendations, examinations and to fill prescriptions to treat your rosacea. Contact your dermatology provider to find out if they offer virtual appointments.
For Your Rosacea Patients with Inflammatory Lesions
Time to surface
Prescribe the topical that helps them get clearer faster and longer 1, 2, a
aA phase 3, investigator-blinded, multicenter, randomized, parallel-group study comparing the efficacy and safety of Soolantra® (ivermectin) Cream, 1% once daily with MetroCream® (metronidazole) Topical Cream, 0.75% twice daily in 962 subjects aged 18 years and older with moderate to severe papulopustular rosacea (Investigator’s Global Assessment [IGA] score of 3 or 4) over a 16-week treatment period (Part A). A total of 757 successfully treated subjects, rated clear or almost clear (IGA score of 0 or 1), continued to the 36-week extension evaluating relapse after a treatment-free period (Part B).1,2
In Part B, subjects were followed every 4 weeks for up to 36 additional weeks (Weeks 16-52). If relapse (defined as IGA score of ≥2 [mild, moderate, or severe]) occurred, subjects were re-treated with the same treatment they had received during the initial 16-week study (Part A). Re-treatment was stopped when subject(s) achieved an IGA of ≤1 (clear or almost clear), with a maximum duration of re-treatment of 16 consecutive weeks to mimic the Part A treatment duration. Several re-treatment periods were permitted.2